

## Mitochondrial DNA, mitochondrial dysfunction, and cardiac manifestations

Sung Ryul Lee<sup>1</sup>, Nari Kim<sup>2</sup>, Yeun Hee Noh<sup>2</sup>, Zhelong Xu<sup>3</sup>, Kyung Soo Ko<sup>2</sup>, Byoung Doo Rhee<sup>2</sup>, Jin Han<sup>2</sup>

<sup>1</sup>Department of Integrated Biomedical Science, College of Medicine, Cardiovascular and Metabolic Disease Center, Inje University, Busan 47392, Korea, <sup>2</sup>National Research Laboratory for Mitochondrial Signaling, Department of Physiology, College of Medicine, Cardiovascular and Metabolic Disease Center, Inje University, Busan 47392, Korea, <sup>3</sup>Department of Physiology and Pathophysiology, Tianjin Medical University, Tainjin 300070, P.R. China

### TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Mitochondria and their maintenance
4. Mitochondrial dysfunction and oxidative stress
5. Oxidative stress, mtDNA mutations, and mtDNA repair system
  - 5.1. Mitochondrial DNA damage
  - 5.2. mtDNA damage-repair system
  - 5.3. Inheritance of mitochondrial mutations
6. Mitochondrial disorders and cardiac manifestations
7. Therapeutic approaches for mitochondrial disorders
8. Conclusion
9. Perspectives
10. Acknowledgements
11. References

### 1. ABSTRACT

Mitochondria, are the powerhouses of cells, have their own DNA (mtDNA), regulate the transport of metabolites and ions, and impact cell physiology, survival, and death. Mitochondrial dysfunction, including impaired oxidative phosphorylation, preferentially affects heart function due to an imbalance of energy supply and demand. Recently, mitochondrial mutations and associated mitochondrial dysfunction were suggested as a causal factor of cardiac manifestations. Oxidative stress largely influences mtDNA stability due to oxidative modifications of mtDNA. Furthermore, the continuous replicative state of mtDNA and presence of minimal nucleoid structure render mitochondria vulnerable to oxidative damage and subsequent mutations, which impair mitochondrial functions. However, the occurrence of mtDNA heteroplasmy in the same mitochondrion or cell and presence of nuclear DNA-encoded mtDNA repair systems raise questions regarding whether oxidative stress-mediated mtDNA mutations are the major driving force in accumulation of mtDNA mutations. Here, we address the possible causes of mitochondrial DNA mutations and their involvement in cardiac manifestations. Current strategies for treatment related to mitochondrial

mutations and/or dysfunction in cardiac manifestations are briefly discussed.

### 2. INTRODUCTION

Mitochondria are extremely specialized organelles that generate adenosine triphosphate (ATP) via the electron transport chain (ETC) and oxidative phosphorylation system (OXPHOS). They are essential for maintaining energy homeostasis in cardiomyocytes, and constitute approximately 30% of the volume of the heart (1, 2). A large amount of ATP is supplied through mitochondria daily to maintain the normal contractile function of the heart (1). In biological systems, turnover of all cellular components is a continuous process and consumes about half of the total energy provision. When the energy supply from mitochondria is limited, the infrastructure of cells gradually disintegrates and eventually cell death occurs (1). The respiratory chain system is composed of over 100 different proteins but only 13 of them are encoded by mitochondrial DNA (mtDNA), which consists of circular, double-stranded DNA (1, 3, 4). Unlike the nucleus, the cell may contain several thousand mitochondria, and each


mitochondrion contains 1–10 copies of mtDNA (5, 6). Mitochondrial morphology is dynamic, and variation in the size and appearance of the cristae can be seen depending on the cell type. Mitochondria form highly dynamic networks and changes in their structure and distribution that are directed by the fusion or fission process are largely associated with metabolic function (7–10). Experimental data suggest that further study of mitochondria is essential for understanding both healthy life and many pathological conditions since numerous biological functions, including respiration and ATP delivery, biosynthesis of amino acids and nucleotides, production of prosthetic groups such as the iron-sulfur cluster and heme, metal homeostasis, and stress signaling and defense responses, are associated with mitochondrial functions (2, 11–13). Therefore, impairment of mitochondrial functions due to primary causes such as mutations in mtDNA or secondary damage from oxidative stress results in cellular dyshomeostasis and is a prototype of mitochondrial diseases (14–19). However, the number of mitochondrial diseases may increase due to nuclear mutations affecting subunits of the ETC complex, defective mtDNA maintenance or replication, and impairment of metabolism (1, 16, 20).

It has been suggested that oxidative stress is a strong inducer of mtDNA mutations (15, 21–24). Increased production of reactive oxygen species (ROS) and their active metabolites over the threshold level induces oxidative stress, resulting in oxidation of proteins (25) and lipids (26), DNA damage (27, 28), and/or accumulation of dysfunctional organelles; these are well-established hallmarks of cardiovascular diseases, neurodegenerative diseases, and age-related complications. Oxidative stress can be practically defined as a disequilibrium between oxidants and antioxidants that favors oxidants, leading to disruption of redox signaling (29, 30). Paradoxically, short-term oxidative stress may play an important role in prevention of aging-associated complications (31), evoking protective signaling by ischemic pre- and post-conditioning (32) and participating in redox signaling to control mitochondrial function (30). Free radicals could increase the rate of mutations such as base changes and oxidative modifications of mtDNA (24, 33, 34). mtDNA oxidation also spontaneously occurs due to ROS induced as byproducts in the mitochondria during respiration (33). Tissue- or cell-damaging conditions such as hypoxia-reoxygenation could produce mtDNA oxidation in animal models as well (35, 36). The free radical theory of aging suggests a central role for the mitochondrion in normal mammalian aging, but recent works challenge the importance of mitochondrial ROS in the progression of aging (37). Recent findings showed that G→T mutations in mtDNA, which is believed to be a distinctive characteristic of oxidative damage to DNA during aging, do not significantly increase with age (38–40). Moreover, mice expressing

error-prone mitochondrial DNA polymerase  $\gamma$  (POL  $\gamma$ ) showed accumulation of substantial burdens of mtDNA mutations that shortened the life-span without remarkable oxidative stress (41–43). In addition, it has been suggested that the concept of mtDNA damage and oxidative stress leading to atherosclerosis may need to be revised due to low correlation between oxidative stress-mediated mtDNA damage and atherosclerosis (39, 40). In addition to mtDNA mutations (Figure 1), decrease or loss of mtDNA copy number (or content) plays a role across a range of prevalent human diseases, including cardiovascular disease and aging (44, 45). Nuclear DNA mutations can largely influence mitochondrial OXPHOS since complexes of the mitochondrial ETC are constituted by both genomes (Figure 2). Although there is strong agreement that mitochondrial energy metabolism, oxidative stress, ROS production, and cell death are highly involved in neurodegeneration or cardiovascular defects, the primary defect and the definitive cause-and-effect relationship leading to the particular pathology are unclear and require in-depth analysis.

Cardiac manifestations may be in the form of structural defects, functional lesions, or both (41, 46). Among the cardiac structures that can be affected, it is the myocardium that is affected the greatest (46, 47). Functional lesions such as conduction abnormalities, systolic dysfunction, arterial hypertension, and heart failure are frequently associated with structural abnormalities. Metabolic changes in the heart have emerged as key mechanisms involved in the development and progression of pathological remodeling. Recently, it has been increasingly recognized that primary and secondary mitochondrial disorders are closely associated with cardiac defects (46, 48–52). Therefore, understanding common cardiac abnormalities based on the mitochondrial background and its clinical presentation will be important to achieve better clinical outcomes (53).

In this review, we briefly summarized the impact of oxidative stress on mtDNA modifications originating intracellularly or from mitochondrial dysfunction. In addition, mitochondrial DNA mutations and the importance of notification to intervene the cardiac manifestations have been briefly addressed. We have presented the current view that mtDNA mutations are not merely dependent on oxidative stress but complex regulatory mechanisms are also involved in accumulation of mtDNA mutations and its final outcome of cardiac manifestations. Current strategies for treatment related to mitochondrial mutations and/or dysfunction in cardiac manifestations have been briefly discussed. However, detailed discussion of human genetic disease related to mtDNA mutations and numerous genes involved in mitochondrial disorders caused by nuclear DNA was omitted due to space limits and the scope of the current review.



**Figure 1.** Human mitochondrial DNA (16,569 base pairs) and pathogenic mutations identified in mitochondrial DNA. Human mitochondrial DNA (mtDNA) codes for seven of the 43 subunits of complex I, one of the 11 subunits of complex III (cytochrome b, CYTB), three of the 13 subunits of complex IV (COX I, II, III) and two of 16 subunits of complex V (ATPases 6 and 8). It also codes for two rRNAs and 22 tRNAs. mtDNA mutations associated with known human genetic diseases and cardiac manifestations are marked as blue (broken arrow) and red (solid arrow), respectively. Mutations in tRNA genes of mitochondrial DNA are frequently found in cardiac manifestations and cause predominantly myopathic phenotypes. Deletion in a large portion of mtDNA sequences results in various forms of cardiomyopathies, ventricular septal defect, dilation of the aortic root, or pulmonary hypertension. ADPD, late-onset *alzheimer's* disease; COX, cytochrome C oxidoreductase; CPEO, chronic progressive external ophthalmoplegia; LHON, Leber's hereditary optic neuropathy; MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; MERRF, myoclonic epilepsy with ragged red fibers; NARP, neuropathy, ataxia, and retinitis pigmentosa; ND1-6, component of rotenone-sensitive NADH-ubiquinone oxidoreductase (complex I); O<sub>H</sub>, heavy-strand origin of replication; P, promoter of heavy and light strands.


Aberrant activation of immune systems can influence the dynamics of mitochondria, but this issue has also not been discussed in this review.

### 3. MITOCHONDRIA AND THEIR MAINTENANCE

mtDNA possesses only 37 genes (Figure 1) but the mitochondrion contains at least 800–1500 proteins whose relative abundance varies between tissues (54–56). Almost all the protein components involved in transcription, replication, and protein synthesis in mitochondria are encoded in the nucleus (Figure 2) and are transported into the mitochondria subsequent to their synthesis in the cytoplasm via the transporter inner membrane (TIM)/ transporter outer membrane (TOM) and other transporter proteins (1, 57, 58). It is noteworthy that the majority of mtDNA-encoded proteins are extremely hydrophobic peptides, and thus those proteins would not be easily imported by the mitochondrial translocation machinery (59). The maintenance of mitochondrial function requires a fine and subtle balance between continuous protein synthesis and degradation. A metabolic labeling study showed that, in general, most mitochondrial

proteins are quite stable over prolonged periods of time, depending on tissue specificity (60). In the rat heart, it is assumed that one mitochondrion per cell is replaced every 40 min and the half-life is 14 days (60, 61); furthermore, this turnover of mitochondria may be related to the circadian cycle (62, 63).

Mitochondrial biogenesis includes mtDNA replication, transcription of mitochondrial RNA, translation of mitochondrial mRNAs, and import of both nuclear-encoded proteins and tRNAs into mitochondria (Fig.2). In addition, mitochondria contain several proteases for controlling protein turnover in the mitochondria to match the need for removal of defective peptides such as misfolded proteins and control gene expression in response to various cellular signals (1, 64). The mtDNA in the cell may be heterogenous. mtDNA in mitochondria is not naked but is packaged into bacterial nucleoid-like structures (65), and thousands of mtDNA molecules are organized in several hundred nucleoids (11, 64–66). At least 21 proteins, including mitochondrial transcription factor A (TFAM), mtSSB (single-stranded DNA-binding protein), and twinkle (a mitochondrial DNA helicase),



**Figure 2.** Mitochondrial dysfunction and cardiac manifestations. Mitochondrial DNA (mtDNA) damage can be induced by oxidative stress and/or failure in maintenance of mtDNAs. Mitochondrial dysfunction, whether caused by mutations of mtDNA or nuclear DNA, could further deteriorate mitochondrial health and result in pathological outcomes. However, the segregation of mutations and the tissue-specific thresholds, which represent biochemical, translational, or phenotypic tolerance, are important in determining the clinical features observed, but other unknown factors must also play a significant role. eNOS; endothelial nitric oxide synthase; NADPH oxidase, nicotinamide adenine dinucleotide phosphate-oxidase; OXPHOS, oxidative phosphorylation complex.

are involved in the building of nucleoid structure (64, 65). Owing to the characteristics of mitochondrial nucleoids, the proportion of mutant to normal mtDNA can shift during the phase of segregation (67) and shows heteroplasmy, which is defined as the presence of at least two populations of mtDNA molecules such as normal (wild type) and mutated DNA, ranging from barely detectable to 100% of cells (1). In mitochondrial DNA replication, POL  $\gamma$ , mtSSB, and twinkle are minimal components of the mtDNA replisome (64). Unlike nuclear DNA synthesis, which is highly dependent on the cell cycle, the pattern of mtDNA synthesis displays less stricter phase specificity (64, 68). During the transcription of mtDNA, mitochondrial RNAs are produced from polycistronic transcripts and undergo processing and modifications to produce mature mRNA (64). The abundance of each mRNA, rRNA, and tRNA is not equal, possibly due to further post-transcriptional modifications that affect transcript processing, maturation, stability, and degradation (69). Although there are many questions regarding the exact molecular machineries for replication and transcription of mtDNA, which are coupled events (3, 64, 69), the proper balance between mtDNA replication, mitochondrial dynamics, mitophagy, and mitochondrial biogenesis ensures continuous turnover of mtDNA. The importance of mitochondrial

genetic information is stressed by the fact that mitochondria preserved very complex and unique machinery to maintain and express the content of mtDNA. Moreover, it has been speculated that proper maintenance of the mitochondrial genome warrants functional mitochondria and further contributes to nuclear genome stability (12, 18).

In order to maintain a healthy mitochondria, several quality control pathways function in the mitochondria (9, 62, 70, 71). As depicted in Figure 2, these quality control systems monitor mitochondrial integrity via antioxidants, DNA repair systems, and mitochondrial unfolded protein response systems, which are involved in sensing or removal of aggregated or misfolded proteins (72). Unlike the nucleus in postmitotic cells, mitochondria are dynamic, in part because they are constantly undergoing fission, which may be necessary to increase the number of mitochondria, and fusion reactions, which may be involved in the exchange of mtDNA to complement deficits in mitochondria carrying mutated genomes (73). In addition, the fission and fusion processes of mitochondria cause dynamic exchange of components, including mtDNA (70). Thus, mitochondrial fission and fusion are intimately linked and determine mitochondrial morphology. Impairment of this regulatory process in



cells may contribute to age-associated accumulation of mtDNA damage. Excessive stress will induce mitophagy and ultimately lead to cell death if not recovered (70). Mitophagy is a specialized autophagic process that also involves lysosomes and leads to degradation of dysfunctional mitochondria through at least two pathways, NIX-based programmed mitophagy and PTEN-induced putative kinase 1 (PINK1)-mediated selective mitophagy (74, 75). Together, these mitochondrial quality control systems form a network that is involved in regulation at the molecular, cellular, and organelle levels (70, 74). Mechanistic insights into the fission/fusion and mitophagic processes would involve discussion of a highly complicated pathway, and a detailed description of this pathway is beyond the scope of the current review. Mitochondria are likely to be fundamental players in regulating the redox state through modulation of NAD<sup>+</sup>/NADH or GSH/GSSG ratios, and thus histone chromatin remodeling and gene expression are influenced by mitochondrial metabolites such as NAD<sup>+</sup> (76, 77). This event is an example of direct crosstalk between mitochondria and the nucleus (12, 13). It has also been suggested that mitochondrial proteins could direct signals to the nucleus to regulate gene expression (12, 78); there are several nuclear transcription factors such as p53 and nuclear hormone receptors, found in both the nucleus and mitochondria, and this kind of crosstalk is necessary to cope with stress and control cell survival and growth (79). Furthermore dual mitochondrial and nuclear localization of the same proteins represent a widespread regulatory circuit for maintaining mitochondrial homeostasis (78)

#### **4. MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS**

In mitochondria, two types of electron transfer are suggested: one is involved in metabolism (high-flux electron transfers) and the other is involved in signaling and metabolic control (low-flux pathways involving protein cysteine or methionine residues, i.e., glutathione, thioredoxin and cysteine/cysteine) (27). Dysfunction of mitochondria can induce leakage of electrons from the ETC and this further augments oxidative stress both in mitochondria and intracellular molecules. Experimentally, mitochondrial dysfunction could be characterized by inhibition of oxygen consumption, collapse of membrane potential, and reduction in ATP (80). As depicted in Figure 2, it is hypothesized that mitochondrial dysfunction can be introduced by perturbations in (a) proteins involved in the formation of respiratory chain complexes; (b) proteins involved in the transport of other proteins into mitochondria; (c) proteins involved in mitochondrial protein synthesis, proper protein folding, prosthetic group preparation, and mounting or functional complex maturation; (d) proteins involved in the delivery of necessary substrates; (e) proteins preventing macromolecule damage during

cellular stress conditions; (f) and proteins involved in mitochondrial biogenesis and mtDNA maintenance (11, 19, 81, 82). Factors such as the following would also cause mitochondrial dysfunction: inflammatory mediators such as tumor necrosis factor  $\alpha$ ; dietary deficiency of vitamins, minerals, or other metabolites; toxic metals such as mercury; mitochondrial toxins such as rotenone or cardiotoxic drugs (83, 84); and disablement of the oxidant-detoxification system (80). The cause-and-effect relationship between mitochondrial dysfunction and oxidative stress has not been completely elucidated. In some cases, the lack of major benefits in intervention trials with ROS scavengers has been reported (85, 86). The final stage of mitochondrial dysfunction induces depolarization of mitochondrial membrane potential and a burst of mitochondrial oxidative/nitrative stress, eventually leading to cell death (87, 88).

#### **5. OXIDATIVE STRESS, mtDNA MUTATIONS, AND mtDNA REPAIR SYSTEM**

Damage to mtDNA and lack of repair of mutated DNA may lead to mitochondrial dysfunction and cell death. The mtDNA copy numbers in specific cells reflect the status of mitochondrial biogenesis, but the exact mechanism underlying the control of mtDNA copy number is still obscure. Human diseases caused by excess mtDNA copy number are rare (17), and much attention has been focused on the putative role of depletion of mtDNA and the complex status of mtDNA mutations associated with mitochondrial dysfunction. For example, large deletions of mtDNA, such as rho<sup>-</sup> or rho<sup>0</sup>, lead to a complete lack of mtDNA and thus complete ETC proteins cannot be synthesized (89). Disease-based epidemiology studies estimate the population prevalence of mtDNA disease at ~1:5000; heteroplasmic mtDNA mutations are found in 1:200 of newborns (90). As depicted in Figure 2, mutation of mtDNA and the accumulation, and segregation of mutated mtDNA may be broadly associated with oxidative stress. However, oxidative stress would not be the sole cause of mitochondrial mutations and subsequent dysfunction of mitochondria since the mutations produced by oxidative modification could be repaired to some extent by the mtDNA repair system and maintenance of mtDNA is almost completely dependent on nuclear-encoded proteins. In addition, removal of malfunctioning mitochondria is influenced by the mitophagic process. Eventually necrotic or apoptotic death of affected cells containing mutated mtDNA or dysfunctional mitochondria will decrease frequency of mutated mtDNA. Clinical manifestations of mtDNA mutations are very complex due to various phenotypic presentations (18). Thus, improved understanding of the quality control in mitochondria would provide greater opportunities for preventing or overcoming mitochondrion mutation/dysfunction-associated complications in humans.

### 5.1. Mitochondrial DNA damage

It has been suggested that three factors make mtDNA particularly vulnerable to mutations (91, 92): First, the mtDNA is localized close to the inner membrane, where free radicals are produced. However, recent findings suggest that mitochondrial nucleoids are not located close to the site of ROS production as expected (93). Second, mtDNA is not extensively condensed and protected by histones but is roughly organized with nucleoid-associated proteins such as the high mobility group (HMG) box family and mitochondrial transcription factor A (TFAM) (66). Thus, tissue-specific loss of TFAM is prone to cause cardiomyopathy, muscle weakness, Parkinson-like neuronal dysfunction, and diabetes (94). Third, mtDNA repair activity is limited as compared to that in the nucleus (95). Covalent modifications of mtDNA in the nucleus are readily detected by the DNA repair system, but some types of DNA repair cannot be found in mammalian mitochondria. Because of the continuous replicative nature of mtDNA, the frequency of mutation in mtDNA can be changed by clonal expansion, even in postmitotic cells, including cardiomyocytes, during cell division or renewal (68).

Oxygen is an essential component of eukaryotic aerobic metabolism and ROS such as oxygen radicals (superoxide ( $O_2^{\cdot-}$ ) and hydroxyl radical ( $OH^{\cdot}$ ), as well as certain non-radical species (hydrogen peroxide and single oxygen)) are generated as byproducts of oxygen consumption, which occurs in mitochondria under normal physiological conditions. Oxidative stress can directly modify the sugar moiety (2'-deoxyribose residue) and DNA nucleobases of mtDNA and leading to the formation of 8-oxo-7,8-dihydroguanine (8-oxoGua), 2,6-diamino-4-hydroxy-5-formamidopyrimidine, and 8-oxo-7,8-dihydroadenine (92). Strangely, high levels of 8-oxo-2'-deoxyguanosine (8-oxodG) were found in the mtDNA of mice null for oxoguanine DNA glycosylase (OGG1), which removes 8-oxoGua from DNA, but this OGG1 deficiency does not cause mitochondrial respiratory dysfunction in the heart and liver of mice (96). This finding may be connected to the fact that a large number of base changes in mtDNA are inert because of the absence of amino acid substitutions, conservative amino acid changes, or occurrence in noncoding regions of the mitochondrial genome, with the exception of specific promoters or replication origin sequences (1, 49). A frequent mitochondrial mutation (Figure 2) is the transition from G to A (<http://www.mitomap.org>); mitochondrial mutations include deletions, insertions, or substitutions affecting a single gene, consistent with misincorporation by POL  $\gamma$  (97) or deamination of cytidine and adenosine (38) as the primary mutagenic events in mtDNA abasic sites, and single- and double-strand breaks and 8-oxoguanine DNA adducts, the major mutagenic lesions generated by ROS (33).

Metabolic disturbances such as imbalance of the deoxyribonucleotide triphosphate (dNTP) pool could indirectly exacerbate some misincorporation events (92). Spontaneous decay of the nucleic acid structure of mtDNA, such as depurination, and the impact of various types of ROS and products generated as a consequence (e.g., lipid peroxides, aldehydes and S-adenosylmethionine) could be involved in DNA modifications (34, 98-100) and cause blockage of transcription or replication, as well as point mutations in mtDNA. Deletions in mtDNA (Figure 2) are more frequently detected in nondividing tissue, such as the cardiac muscle and brain, rather than cells with a relatively short half-life, such as blood cells, and result in a mosaic pattern, as observed in histochemical staining. Theoretically, two pathways have been suggested to be involved in the occurrence of mtDNA deletion (92): Deletions of mtDNA are generated during replication by slipped-strand homology in repetitive sequences, and deletion in mtDNA occurs during repair of double-stranded breaks (92). Irradiation (101, 102), chemical agents such as *t*-butyl hydroperoxide (103), and ultraviolet light can generate double-strand breaks which serve as critical DNA lesions that might lead to genome rearrangements (104-106). The molecular mechanism leading to deletion in mtDNA, particularly large-scale deletions varying in size from 1.3. to 8 kb, are still poorly understood (92) but these deletions are considered as a common cause of human mitochondrial diseases and are also considered to be involved in aging (1, 107-109).

### 5.2. mtDNA damage–repair system

Combined action of mitochondrial fission and mitophagy could provide an elegant, self-purifying mechanism for removal of defective mtDNA molecules from the cellular pool (95, 110). So far, there is no evidence that mutated mtDNA could be selectively degraded by any of the mitochondrial nucleases. When the extent of mtDNA damage exceeds the repair and buffering capacities of mitochondria leading to respiratory chain deficiency and mitochondrial dysfunction, mutated mtDNA should be deleted from the pool. Due to the highly oxidizing environment of the mitochondria even under normal conditions, the lagging strand of mtDNA is kept in the single-stranded condition for a prolonged time during mtDNA replication, and thus spontaneous mutations will easily develop. In mtDNA replication, there are increasing possibilities that misincorporation of bases or uncorrected mutations is caused by POL  $\gamma$  due to its low fidelity or other factors. Several DNA repair systems were identified: direct reversal (111), base excision repair (92, 95), mismatch repair, nucleotide excision repair, and DNA double-stranded break repair (95). The major DNA repair pathway in mitochondria is excision repair, which includes the following: (a) Base excision repair (BER), which occurs in both

the nucleus and mitochondria. This BER pathway includes recognition and incision by DNA glycosylase glycosylases (OGG1; 8-oxoguanine DNA glycosylase (UNG); uracil DNA glycosylase (NTH1); endonuclease III-like 1 (NEIL1/2); Nei endonuclease VIII-like 1 and 2 (MUTYH); mammalian homolog of *Escherichia coli* MutY (MTH1); an 8-oxoGTPase present both in the nucleus and mitochondria), abasic-site processing by apurinic/apyrimidinic endonucleases, DNA synthesis, and then final ligation of single-strand nicks, conducted by POL  $\gamma$ , which resynthesizes missing DNA patches, and DNA ligase (LIG3), which seals the DNA fragments (73). (b) Post-replicative mismatch repair in base mismatches and 1–4 nucleotides insertion/deletion loops. (c) Recombinational repair system in double-strand breaks (92, 95). Therefore, the accumulation of mtDNA mutation is not only determined by the higher mtROS formation rates but also by the status of the mitochondrial DNA repair system (112). However, it is unclear whether oxidative stress could directly or indirectly affect the mtDNA repair system.

### 5.3. Inheritance of mitochondrial mutations


The mutation frequency of mtDNA is higher than that of nuclear DNA by several orders of magnitude (113, 114). Although this difference was initially attributed to increased mtDNA damage due to elevated concentrations of endogenous ROS produced as byproducts of oxidative phosphorylation (21, 41), many recent studies argue against any significant contribution of oxidative damage in accumulation of mtDNA mutations (34, 37). In line with this, dynamin related protein 1 (Drp1)-mediated mitochondrial fission and mitofusin (MFN) 1, MFN2 and optic atrophy factor 1 (OPA1) directed fusion process will contribute to the segregation of affected mtDNA (7, 8). Inheritance of mitochondrial DNA mutations is dependent on the mutation type, such as only blockage of replication or possible propagation of a novel mutation (24, 115), and phenotypic manifestations take months or years (1). The distinction between variants with point mutations and variants with large deletions will be an important factor in inheritance of mitochondrial mutations (Figure 1). It is conceivable that mtDNAs with some deletions are more rapidly replicated and thus have a selective advantage in propagation compared to normal counterparts (92). This might be related to the fact that the fraction of deleted mtDNAs in muscle also increases with age and is also possibly higher in the brain (116).

## 6. MITOCHONDRIAL DISORDERS AND CARDIAC MANIFESTATIONS

The constantly beating heart is the organ with the greatest oxygen consumption in a resting body (117). Although mitochondrial disorders are extraordinarily diverse from the view of phenotypical presentation and

genetic background (74), mitochondrial dysfunction associated with mtDNA mutation appears to play a role in the development of heart failure (41, 118–121). Severe exercise limitation is typical of mitochondrial cardiomyopathies with associated skeletal myopathy, and further investigation frequently reveals premature lactate acidosis during exercise (41). Various mtDNA mutations have been detected in heart tissue (Figure 1). The cardiac manifestations in mitochondrial disorders is gradually being recognized but their frequency, sex distribution, age at onset, affection of other organs, or affected cardiac tissue is diverse (41, 46, 49, 90). In protein-coding genes of mtDNA, the most frequently identified biochemical abnormalities are related to deficiencies of complexes I and IV (122). A large number of mutations in mtDNA genes have been mapped to mt-tRNA loci possessing a high frequency of point mutations, despite accounting for just 5–10% of the mtDNA (Figure 1). Furthermore, mischarging of mt-tRNAs occurs more frequently as a consequence of certain mutations and leads to a gain or loss of function of the protein involved (123, 124). Besides mtDNA mutations, impaired autophagic clearance of protein aggregates or deteriorating mitochondria will have multiple consequences, including increased arrhythmia risk, decreased contractile function, reduced tolerance to ischemic stress, and increased inflammation; thus autophagy represents a potentially important therapeutic target to mitigate the cardiac consequences of aging (125).

Cardiac manifestations in mitochondrial disorders includes cardiomyopathy, arrhythmia, heart failure, pulmonary hypertension, dilation of the aortic root, pericardial effusion, coronary heart disease, autonomous nervous system dysfunction, congenital heart defects, or sudden cardiac death with the syndromic or non-syndromic phenotype (41, 46, 48–50, 126, 127). Unlike mitochondrial disorders associated with neurodegeneration or neurological disorders that are largely noticeable (16, 111, 128), cardiac manifestations in mitochondrial disorders are currently underestimated (41, 46, 48) but these mitochondria-associated complications serve as an important predictor of morbidity and mortality (48). It should be stressed that tolerable mutations in mtDNA do not eventually lead to malfunction of mitochondria (Figure 2) because of the existence of normal mitochondria and the threshold in the context of mitochondrial deficit for the expression of the disease depending on tissue specificity (15). For example, in certain cases, the presence of approximately 10% of wild-type mtDNA is sufficient to maintain a normal respiratory rate and at least 80–90% mtDNA deletion is required for compromised complex IV activity (23, 128). In addition, it is recognized that the energy threshold of mitochondria initiating pathological changes is different from that in the original tissue (128). These complex behaviors of mtDNA mutations may create



**Figure 3.** Therapeutic approaches for dysfunctional mitochondria. Replacement of aberrant mitochondria with healthy mitochondria is a promising strategy but is limited by the available techniques and poor understanding of the complex behavior of mitochondrial genetics, which creates a hurdle for clinical development. Additional strategies include the following: (a) relieving metabolic stress and increasing mitochondrial biogenesis, (b) improving the efficiency of oxidative phosphorylation or the mitochondrial protein synthesis system, (c) restoring mitochondrial DNA (mtDNA) homeostasis or shifting mtDNA heteroplasmy, (d) rescuing defects of mitochondrially encoded proteins by recoding for nuclear expression and mitochondrial targeting. dNTP, deoxyribonucleotide triphosphate.

another hurdle in identifying mitochondrion-associated cardiac manifestations. In addition, the mitochondrial dysfunction noted in connection with cardiac manifestations is not limited to mtDNA mutations but is also related to nuclear DNA mutations and impairment of mitochondrial quality control system.

## 7. THERAPEUTIC APPROACHES FOR MITOCHONDRIAL DISORDERS

Mitochondrial disorders-associated cardiac manifestations are categorized as hereditary or sporadic disorders (129). Although interesting and often imaginative therapeutic strategies have been successful *in vitro*, therapeutic regimens for mitochondrial disorders with cardiac manifestations need more extensive development based on mitochondrial genetics and quality control system. As briefly outlined in Figure 3, treatment guidelines for mitochondrial disorders are generally based on supportive or complementary management of the symptoms rather than their genetic correction (41, 71, 81, 130, 131). First, mitochondrial biogenesis is considered as a set of molecular events by which cells replace or increase their mitochondria through the proliferation of pre-existing organelles, based on the activation of peroxisome proliferator activated receptor- $\gamma$  coactivator-1 $\alpha$  (PGC-1 $\alpha$ ) and AMP-dependent kinase (41, 76, 132, 133). In addition, it is not yet clear but there is another attempt to regulate

mitochondrial biogenesis through putative estrogen receptor (133, 134), glucocorticoid receptor (135), and thyroid receptor (71) binding sites located in mtDNA. It should also be considered that mitochondrial biogenesis can be engineered by exercise programs (136) and has been shown to be safe and beneficial for patients with mitochondrial disease (137). Second, interventional efforts for modulation of respiratory chain function have been extensively investigated in an experimental setting, and currently significant efforts are being undertaken to translate these results to applications in humans (81, 133). The literature on the efficacy of these putative proliferators (e.g., bezafibrate; the polyphenols resveratrol, epicatechin, and ribonucleotide ribonucleotide 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR); coenzyme Q10 and its analogs) in ameliorating mitochondrial dysfunction is complex and often contradictory (133), and this topic requires further study. Bypassing the pathogenic mechanism through removal of noxious metabolites has also been attempted for correction of biochemical defects in mitochondria. For example, administration of dichloroacetate (DCA), which is a pyruvate dehydrogenase complex (PDH) kinase inhibitor, reduced lactate production in primary mitochondrial disorder and improved brain function (138). Third, many mitochondrial disorders are due to mutations in genes encoding mt-tRNAs (132), leading to a deficiency in mitochondrial protein synthesis and subsequent abnormality of oxidative phosphorylation



(137). Therefore, screening of small molecules to identify compounds that can stabilize mt-tRNAs is worth investigating (19). Finally, gene therapy and strategies aimed to correct, bypass, and avoid the transmission of the molecular defect of mitochondria are gaining attention in recent years and the results are promising (121, 133). For the treatment of mtDNA-oriented disorders, the removal and/or prevention of continuous propagation of the mutated genome will be favorable to obtaining a therapeutic outcome. Trials are being performed on selective degradation of mutated mtDNA by using mitochondrial-targeted zinc finger nucleases (137, 139-141). These trials are focused on switching heteroplasmy through increasing the amount of wild-type mtDNA and thereby correcting the biochemical deficiency. In addition, rescue of the mitochondrial phenotype after lentiviral adeno-associated virus delivery of a wild-type copy of the candidate gene has been under investigation (19, 142). Recently, there has been considerable interest in the CRISPR-Cas9-mediated genome editing process in mitochondrial disorders (137), or carrier-free targeting of the mitochondrially importable RNA into living human cells was designed (143, 144). However, mitochondrial gene therapy is not simple since DNA or RNA molecules do not easily penetrate mitochondria *in vivo*. In clinical applications, there are great limitations regarding safe delivery of the therapeutic agent into mitochondria in an organ-specific manner (145). In addition, therapeutic interventions for mitochondrial diseases in cardiac manifestations should prevent death of cardiomyocytes and at the same time be efficient with respect to their effects on mutated mtDNA or malfunctioning mitochondria before reaching its limit in the affected cell.

## 8. CONCLUSION

Relatively less data are available on the pathogenesis of cardiac manifestations in relation to mitochondrial involvement, which may be related with mitochondrial dysfunction at various levels depending on the outcome of the mutated gene (46) and current limitations of diagnostic tools (Figure 1). Abnormalities in mitochondrial function that contribute or lead to human disease, especially in the heart, can be derived from several sources such as innate mitochondrial defects, inflammation, hypoxia-reoxygenation, ionizing radiation, or aging. Oxidative mtDNA damage would be a cause but not the sole determinant in producing mtDNA mutations. When the amount of mutated mtDNA exceeds the recovery potential of mitochondrial repair, mutated mtDNA accumulates in mitochondria. Moreover, the majority of proteins involved in mitochondrial biogenesis and maintenance and mtDNA replication are controlled by nuclear DNA and are transported into mitochondria (Figure 2). Therefore, the rate of mitochondrial mutations can also be affected by the status of nuclear DNA and mitochondrial

transport apparatus. The extent of involvement of oxidative stress in accumulation of mtDNA mutations and the cardiac phenotypic manifestations will need further validations through experiments. Currently, cardiac manifestations in mitochondrial disorders are underestimated and causes of mitochondrial disorders are not clearly demonstrated. Therefore, exact identification of mitochondria-mediated cardiac manifestations is necessary. In addition, developments of clinically applicable strategies for controlling mitochondrial functions, correcting mtDNA mutations, controlling the biogenesis, and quality control systems will be promising in treating heart dysfunction or failure.

## 9. PERSPECTIVES

Both the nuclear and mitochondrial genome may be strongly connected to susceptibility to heart failure, the speed of disease progression, or the response to pharmacologic therapy (131). In clinical situations, identification of mitochondrial dysfunction associated with cardiac manifestations, with a syndromic or non-syndromic phenotype, is not easy, since sampling of the myocardium for detecting mitochondrial dysfunction and mtDNA mutations is not a routine operative procedure (46). Complex genetic variations in mtDNA in the same population is another hurdle for diagnosis and for genetic counseling, which is dependent on accurate molecular genetic diagnosis and current possible regimens for intervention (16). It is believed that mitochondrial mutations and the subsequent dysfunction of mitochondria are not directly associated with oxidative stress, and therefore, greater caution is required to interpret the etiologies of mitochondrial dysfunction associated with cardiac manifestations. In addition, it is clear that the understanding of mitochondrial genetics will lead to improved diagnosis as well as novel ways to treat severe mitochondrial dysfunction associated with cardiac manifestations.

## 10. ACKNOWLEDGEMENTS

Drs Sung Ryul Lee, Nari Kim equally contributed this work. We apologize for the vast number of outstanding publications that could not be cited because of space limitations. This work was supported by the Priority Research Centers Program (2010-0020224) and the Basic Science Research Program (2012R1A2A1A03007595 and 2015R1D1A3A01015596) through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science, and Technology.

## 11. REFERENCES

1. Scheffler, I. E.: Mitochondria. John Wiley & Sons, Inc., New Jersey (2008)  
DOI: 10.1016/j.cub.2006.06.054

2. McBride, H. M., Neuspiel, M., Wasiak, S.: Mitochondria: more than just a powerhouse. *Curr Biol*, 16, R551-60 (2006)  
DOI: 10.1016/j.cub.2006.06.054
3. Bonawitz, N. D., Clayton, D. A., Shadel, G. S.: Initiation and beyond: multiple functions of the human mitochondrial transcription machinery. *Mol Cell*, 24, 813-25 (2006)  
DOI: 10.1016/j.molcel.2006.11.024
4. Claros, M. G., Perea, J., Shu, Y., Samatey, F. A., Popot, J. L., Jacq, C.: Limitations to *in vivo* import of hydrophobic proteins into yeast mitochondria. The case of a cytoplasmically synthesized apocytochrome b. *Eur J Biochem*, 228, 762-71 (1995)  
DOI: 10.1111/j.1432-1033.1995.0762m.x
5. Bogenhagen, D., Clayton, D. A.: The number of mitochondrial deoxyribonucleic acid genomes in mouse L and human HeLa cells. Quantitative isolation of mitochondrial deoxyribonucleic acid. *J Biol Chem*, 249, 7991-5 (1974)
6. Garesse, R., Vallejo, C. G.: Animal mitochondrial biogenesis and function: a regulatory cross-talk between two genomes. *Gene*, 263, 1-16 (2001)  
DOI: 10.1016/S0378-1119(00)00582-5
7. Frazier, A. E., Kiu, C., Stojanovski, D., Hoogenraad, N. J., Ryan, M. T.: Mitochondrial morphology and distribution in mammalian cells. *Biol Chem*, 387, 1551-8 (2006)  
DOI: 10.1515/BC.2006.193
8. Vasquez-Trincado, C., Garcia-Carvajal, I., Pennanen, C., Parra, V., Hill, J. A., Rothermel, B. A., Lavandro, S.: Mitochondrial dynamics, mitophagy and cardiovascular disease. *J Physiol* (2015)  
DOI: 10.1113/JP271301
9. Biala, A. K., Dhingra, R., Kirshenbaum, L. A.: Mitochondrial dynamics: Orchestrating the journey to advanced age. *J Mol Cell Cardiol*, 83, 37-43 (2015)  
DOI: 10.1016/j.yjmcc.2015.04.015
10. Yin, F., Cadenas, E.: Mitochondria: The Cellular Hub of the Dynamic Coordinated Network. *Antioxidants & Redox Signaling*, 22, 961-964 (2015)  
DOI: 10.1089/ars.2015.6313
11. Kaniak-Golik, A., Skoneczna, A.: Mitochondria-nucleus network for genome stability. *Free Radic Biol Med*, 82, 73-104 (2015)  
DOI: 10.1016/j.freeradbiomed.2015.01.013
12. da Cunha, F. M., Torelli, N. Q., Kowaltowski, A. J.: Mitochondrial Retrograde Signaling: Triggers, Pathways, and Outcomes. *Oxidative Medicine and Cellular Longevity*, 2015, 482582 (2015)  
DOI: 10.1155/2015/482582
13. Guha, M., Avadhani, N. G.: Mitochondrial Retrograde Signaling at the crossroads of tumor bioenergetics, genetics and epigenetics. *Mitochondrion*, 13, 10.1016/j.mito.2013.08.007 (2013)
14. Huang, H., Manton, K. G.: The role of oxidative damage in mitochondria during aging: a review. *Front Biosci*, 9, 1100-17 (2004)  
DOI: 10.2741/1298
15. Wallace, D. C.: Mitochondrial diseases in man and mouse. *Science*, 283, 1482-8 (1999)  
DOI: 10.1126/science.283.5407.1482
16. Schapira, A. H. V.: Mitochondrial diseases. *The Lancet*, 379, 1825-1834 (2012)  
DOI: 10.1016/S0140-6736(11)61305-6
17. Clay Montier, L. L., Deng, J. J., Bai, Y.: Number matters: control of mammalian mitochondrial DNA copy number. *Journal of Genetics and Genomics*, 36, 125-131 (2009)  
DOI: 10.1016/S1673-8527(08)60099-5
18. Chen, C., Chen, Y., Guan, M.-X.: A peep into mitochondrial disorder: multifaceted from mitochondrial DNA mutations to nuclear gene modulation. *Protein & Cell*, 6, 862-870 (2015)  
DOI: 10.1007/s13238-015-0175-z
19. Lightowlers, R. N., Taylor, R. W., Turnbull, D. M.: Mutations causing mitochondrial disease: What is new and what challenges remain? *Science*, 349, 1494-9 (2015)  
DOI: 10.1126/science.aac7516
20. Gaspard, G. J., McMaster, C. R.: Cardiolipin metabolism and its causal role in the etiology of the inherited cardiomyopathy Barth syndrome. *Chemistry and Physics of Lipids*, 193, 1-10 (2015)  
DOI: 10.1016/j.chemphyslip.2015.09.005
21. Shigenaga, M. K., Hagen, T. M., Ames, B. N.: Oxidative damage and mitochondrial

- decay in aging. *Proceedings of the National Academy of Sciences*, 91, 10771-10778 (1994)  
DOI: 10.1073/pnas.91.23.10771
22. Kirkinezos, I. G., Moraes, C. T.: Reactive oxygen species and mitochondrial diseases. *Seminars in Cell & Developmental Biology*, 12, 449-457 (2001)  
DOI: 10.1006/scdb.2001.0282
23. Mazat, J. P., Rossignol, R., Malgat, M., Rocher, C., Faustin, B., Letellier, T.: What do mitochondrial diseases teach us about normal mitochondrial functions that we already knew: threshold expression of mitochondrial defects. *Biochim Biophys Acta*, 1504, 20-30 (2001)  
DOI: 10.1016/S0005-2728(00)00236-X
24. Cooke, M. S., Evans, M. D., Dizdaroglu, M., Lunec, J.: Oxidative DNA damage: mechanisms, mutation, and disease. *The FASEB Journal*, 17, 1195-1214 (2003)  
DOI: 10.1096/fj.02-0752rev
25. Davey, G. P., Peuchen, S., Clark, J. B.: Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. *J Biol Chem*, 273, 12753-7 (1998)  
DOI: 10.1074/jbc.273.21.12753
26. Leon, L. J., Gustafsson, A. B.: Staying young at heart: Autophagy and adaptation to cardiac aging. *J Mol Cell Cardiol* (2015)  
DOI: 10.1016/j.yjmcc.2015.11.006
27. Jones, D. P.: Disruption of mitochondrial redox circuitry in oxidative stress. *Chem Biol Interact*, 163, 38-53 (2006)  
DOI: 10.1016/j.cbi.2006.07.008
28. Sies, H., Jones, D.: Oxidative Stress\*. In: *Encyclopedia of Stress (Second Edition)*. Ed Fink, G. Academic Press, New York (2007)  
DOI: 10.1016/B978-012373947-6.00285-3
29. Go, Y.-M., Jones, D. P.: Thiol/disulfide redox states in signaling and sensing. *Critical reviews in biochemistry and molecular biology*, 48, 173-181 (2013)  
DOI: 10.3109/10409238.2013.764840
30. Schulz, E., Wenzel, P., Munzel, T., Daiber, A.: Mitochondrial redox signaling: Interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. *Antioxid Redox Signal*, 20, 308-24 (2014)  
DOI: 10.1089/ars.2012.4609
31. Ristow, M., Schmeisser, S.: Extending life span by increasing oxidative stress. *Free Radical Biology and Medicine*, 51, 327-336 (2011)  
DOI: 10.1016/j.freeradbiomed.2011.05.010
32. Di Lisa, F., Canton, M., Carpi, A., Kaludercic, N., Menabo, R., Menazza, S., Semenzato, M.: Mitochondrial injury and protection in ischemic pre- and postconditioning. *Antioxid Redox Signal*, 14, 881-91 (2011)  
DOI: 10.1089/ars.2010.3375
33. Bjelland, S., Seeberg, E.: Mutagenicity, toxicity and repair of DNA base damage induced by oxidation. *Mutation Research/ Fundamental and Molecular Mechanisms of Mutagenesis*, 531, 37-80 (2003)  
DOI: 10.1016/j.mrfmmm.2003.07.002
34. Gruber, J., Schaffer, S., Halliwell, B.: The mitochondrial free radical theory of ageing--where do we stand? *Front Biosci*, 13, 6554-79 (2008)  
DOI: 10.2741/3174
35. Tsuruya, K., Furuichi, M., Tominaga, Y., Shinozaki, M., Tokumoto, M., Yoshimitsu, T., Fukuda, K., Kanai, H., Hirakata, H., Iida, M., Nakabeppu, Y.: Accumulation of 8-oxoguanine in the cellular DNA and the alteration of the OGG1 expression during ischemia-reperfusion injury in the rat kidney. *DNA Repair*, 2, 211-229 (2003)  
DOI: 10.1016/S1568-7864(02)00214-8
36. Lee, H.-M., Wang, C., Hu, Z., Greeley, G. H., Makalowski, W., Hellmich, H. L., Englander, E. W.: Hypoxia induces mitochondrial DNA damage and stimulates expression of a DNA repair enzyme, the Escherichia coli MutY DNA glycosylase homolog (MYH), *in vivo*, in the rat brain. *Journal of Neurochemistry*, 80, 928-937 (2002) doi:10.1046/j.0022-DOI: 10.1046/j.0022-3042.2002.00774.x
37. Payne, B. A. I., Chinnery, P. F.: Mitochondrial dysfunction in aging: Much progress but many unresolved questions. *Biochimica et Biophysica Acta*, 1847, 1347-1353 (2015)  
DOI: 10.1016/j.bbabi.2015.05.022
38. Kennedy, S. R., Salk, J. J., Schmitt, M. W., Loeb, L. A.: Ultra-Sensitive Sequencing Reveals an Age-Related Increase in Somatic Mitochondrial Mutations That Are Inconsistent with Oxidative Damage. *PLoS Genetics*, 9, e1003794 (2013)  
DOI: 10.1371/journal.pgen.1003794

39. Davidson, S. M., Yellon, D. M.: Mitochondrial DNA Damage, Oxidative Stress, and Atherosclerosis: Where There Is Smoke There Is Not Always Fire. *Circulation*, 128, 681-683 (2013)  
DOI: 10.1161/CIRCULATIONAHA.113.004531
40. Yu, E., Calvert, P. A., Mercer, J. R., Harrison, J., Baker, L., Figg, N. L., Kumar, S., Wang, J. C., Hurst, L. A., Obaid, D. R., Logan, A., West, N. E. J., Clarke, M. C. H., Vidal-Puig, A., Murphy, M. P., Bennett, M. R.: Mitochondrial DNA Damage Can Promote Atherosclerosis Independently of Reactive Oxygen Species Through Effects on Smooth Muscle Cells and Monocytes and Correlates With Higher-Risk Plaques in Humans. *Circulation*, 128, 702-712 (2013)  
DOI: 10.1161/CIRCULATIONAHA.113.002271
41. Schwarz, K., Siddiqi, N., Singh, S., Neil, C. J., Dawson, D. K., Frenneaux, M. P.: The breathing heart - mitochondrial respiratory chain dysfunction in cardiac disease. *Int J Cardiol*, 171, 134-43 (2014)  
DOI: 10.1016/j.ijcard.2013.12.014
42. Trifunovic, A., Hansson, A., Wredenberg, A., Rovio, A. T., Dufour, E., Khvorostov, I., Spelbrink, J. N., Wibom, R., Jacobs, H. T., Larsson, N.-G.: Somatic mtDNA mutations cause aging phenotypes without affecting reactive oxygen species production. *Proceedings of the National Academy of Sciences of the United States of America*, 102, 17993-17998 (2005)  
DOI: 10.1073/pnas.0508886102
43. Kujoth, G. C., Hiona, A., Pugh, T. D., Someya, S., Panzer, K., Wohlgemuth, S. E., Hofer, T., Seo, A. Y., Sullivan, R., Jobling, W. A., Morrow, J. D., Van Remmen, H., Sedivy, J. M., Yamasoba, T., Tanokura, M., Weindrich, R., Leeuwenburgh, C., Prolla, T. A.: Mitochondrial DNA Mutations, Oxidative Stress, and Apoptosis in Mammalian Aging. *Science*, 309, 481-484 (2005)  
DOI: 10.1126/science.1112125
44. Herrera, A., Garcia, I., Gaytan, N., Jones, E., Maldonado, A., Gilkerson, R.: Endangered species: mitochondrial DNA loss as a mechanism of human disease. *Front Biosci (Schol Ed)*, 7, 109-24 (2015)  
DOI: 10.2741/428
45. McCormick, E. M., Kenyon, L., Falk, M. J.: Desmin common mutation is associated with multi-systemic disease manifestations and depletion of mitochondria and mitochondrial DNA. *Frontiers in Genetics*, 6, 199 (2015)  
DOI: 10.3389/fgene.2015.00199
46. Finsterer, J., Kothari, S.: Cardiac manifestations of primary mitochondrial disorders. *Int J Cardiol*, 177, 754-63 (2014)  
DOI: 10.1016/j.ijcard.2014.11.014
47. Dominic, E. A., Ramezani, A., Anker, S. D., Verma, M., Mehta, N., Rao, M.: Mitochondrial cytopathies and cardiovascular disease. *Heart*, 100, 611-618 (2014)  
DOI: 10.1136/heartjnl-2013-304657
48. Bates, M. G. D., Bourke, J. P., Giordano, C., d'Amati, G., Turnbull, D. M., Taylor, R. W.: Cardiac involvement in mitochondrial DNA disease: clinical spectrum, diagnosis, and management. *European Heart Journal*, 33, 3023-3033 (2012)  
DOI: 10.1093/eurheartj/ehs275
49. Limongelli, G., Masarone, D., D'Alessandro, R., Elliott, P. M.: Mitochondrial diseases and the heart: an overview of molecular basis, diagnosis, treatment and clinical course. *Future Cardiol*, 8, 71-88 (2012)  
DOI: 10.2217/fca.11.79
50. Moutagne, D., Pentiah, A. D.: Mitochondrial cardiomyopathy and related arrhythmias. *Card Electrophysiol Clin*, 7, 293-301 (2015)  
DOI: 10.1016/j.ccep.2015.03.008
51. Pohjoismäki, J. L. O., Boettger, T., Liu, Z., Goffart, S., Szibor, M., Braun, T.: Oxidative stress during mitochondrial biogenesis compromises mtDNA integrity in growing hearts and induces a global DNA repair response. *Nucleic Acids Research*, 40, 6595-6607 (2012)  
DOI: 10.1093/nar/gks301
52. Ritzenthaler, T., Luis, D., Hullin, T., Fayssoil, A.: (Cardiac manifestations of mitochondrial diseases). *Presse Med*, 44, 492-7 (2015)  
DOI: 10.1016/j.lpm.2015.01.008
53. Thornton, B., Cohen, B., Copeland, W., Maria, B. L.: Mitochondrial Disease: Clinical Aspects, Molecular Mechanisms, Translational Science, and Clinical Frontiers. *Journal of child neurology*, 29, 1179-1207 (2014)  
DOI: 10.1177/0883073814537379
54. Johnson, D. T., Harris, R. A., French, S., Blair, P. V., You, J., Bemis, K. G., Wang,



- M.,Balaban, R. S.: Tissue heterogeneity of the mammalian mitochondrial proteome. *Am J Physiol Cell Physiol*, 292, C689-97 (2007)  
DOI: 10.1152/ajpcell.00108.2006
55. Mootha, V. K., Bunkenborg, J., Olsen, J. V., Hjerrild, M., Wisniewski, J. R., Stahl, E., Bolouri, M. S., Ray, H. N., Sihag, S., Kamal, M., Patterson, N., Lander, E. S.,Mann, M.: Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. *Cell*, 115, 629-40 (2003)  
DOI: 10.1016/S0092-8674(03)00926-7
56. Meisinger, C., Sickmann, A.,Pfanner, N.: The Mitochondrial Proteome: From Inventory to Function. *Cell*, 134, 22-24 (2008)  
DOI: 10.1016/j.cell.2008.06.043
57. Suzuki, T., Nagao, A.,Suzuki, T.: Human Mitochondrial tRNAs: Biogenesis, Function, Structural Aspects, and Diseases. *Annual Review of Genetics*, 45, 299-329 (2011)  
DOI: 10.1146/annurev-genet-110410-132531
58. Horvath, S. E., Rampelt, H., Oeljeklaus, S., Warscheid, B., van der Laan, M.,Pfanner, N.: Role of membrane contact sites in protein import into mitochondria. *Protein Sci*, 24, 277-97 (2015)  
DOI: 10.1002/pro.2625
59. MacKenzie, J.A.,Payne, R. M.: Mitochondrial protein import and human health and disease. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, 1772, 509-523 (2007)  
DOI: 10.1016/j.bbadis.2006.12.002
60. Kim, T.-Y., Wang, D., Kim, A. K., Lau, E., Lin, A. J., Liem, D. A., Zhang, J., Zong, N. C., Lam, M. P. Y.,Ping, P.: Metabolic Labeling Reveals Proteome Dynamics of Mouse Mitochondria. *Molecular & Cellular Proteomics : MCP*, 11, 1586-1594 (2012)  
DOI: 10.1074/mcp.M112.021162
61. Rabinowitz, M.,Zak, R.: Mitochondria and cardiac hypertrophy. *Circulation Research*, 36, 367-76 (1975)  
DOI: 10.1161/01.RES.36.3.367
62. Stotland, A.,Gottlieb, R. A.: Mitochondrial quality control: Easy come, easy go. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, 1853, 2802-2811 (2015)  
DOI: 10.1016/j.bbamcr.2014.12.041
63. Gong, C., Li, C., Qi, X., Song, Z., Wu, J., Hughes, M. E.,Li, X.: The daily rhythms of mitochondrial gene expression and oxidative stress regulation are altered by aging in the mouse liver. *Chronobiology International*, 32, 1254-1263 (2015)  
DOI: 10.3109/07420528.2015.1085388
64. Falkenberg, M., Larsson, N.-G.,Gustafsson, C. M.: DNA Replication and Transcription in Mammalian Mitochondria. *Annual Review of Biochemistry*, 76, 679-699 (2007)  
DOI: 10.1146/annurev.biochem.76.060305.152028
65. Wang, Y.,Bogenhagen, D. F.: Human Mitochondrial DNA Nucleoids Are Linked to Protein Folding Machinery and Metabolic Enzymes at the Mitochondrial Inner Membrane. *Journal of Biological Chemistry*, 281, 25791-25802 (2006)  
DOI: 10.1074/jbc.M604501200
66. Kucej, M.,Butow, R. A.: Evolutionary tinkering with mitochondrial nucleoids. *Trends in Cell Biology*, 17, 586-592 (2007)  
DOI: 10.1016/j.tcb.2007.08.007
67. Dunbar, D. R., Moonie, P. A., Jacobs, H. T.,Holt, I. J.: Different cellular backgrounds confer a marked advantage to either mutant or wild-type mitochondrial genomes. *Proceedings of the National Academy of Sciences*, 92, 6562-6566 (1995)  
DOI: 10.1073/pnas.92.14.6562
68. Bogenhagen, D.,Clayton, D. A.: Mouse L cell mitochondrial DNA molecules are selected randomly for replication throughout the cell cycle. *Cell*, 11, 719-727 (1977)  
DOI: 10.1016/0092-8674(77)90286-0
69. Rackham, O., Mercer, T. R.,Filipovska, A.: The human mitochondrial transcriptome and the RNA-binding proteins that regulate its expression. *Wiley Interdiscip Rev RNA*, 3, 675-95 (2012)  
DOI: 10.1002/wrna.1128
70. Held, N. M.,Houtkooper, R. H.: Mitochondrial quality control pathways as determinants of metabolic health. *Bioessays*, 37, 867-76 (2015)  
DOI: 10.1002/bies.201500013
71. Suliman, H. B.,Piantadosi, C. A.: Mitochondrial Quality Control as a Therapeutic Target. *Pharmacological Reviews*, 68, 20-48 (2016)  
DOI: 10.1124/pr.115.011502

72. Arnould, T., Michel, S., Renard, P.: Mitochondria Retrograde Signaling and the UPR(mt): Where Are We in Mammals? *International Journal of Molecular Sciences*, 16, 18224-18251 (2015)  
DOI: 10.3390/ijms160818224
73. Gredilla, R.: DNA damage and base excision repair in mitochondria and their role in aging. *J Aging Res*, 2011, 257093 (2010)
74. Scheibye-Knudsen, M., Fang, E. F., Croteau, D. L., Wilson Iii, D. M., Bohr, V. A.: Protecting the mitochondrial powerhouse. *Trends in Cell Biology*, 25, 158-170 (2015)  
DOI: 10.1016/j.tcb.2014.11.002
75. Youle, R. J., Narendra, D. P.: Mechanisms of mitophagy. *Nat Rev Mol Cell Biol*, 12, 9-14 (2011)  
DOI: 10.1038/nrm3028
76. Valero, T.: Mitochondrial biogenesis: pharmacological approaches. *Curr Pharm Des*, 20, 5507-9 (2014)  
DOI: 10.2174/138161282035140911142118
77. Kumar, S., Lombard, D. B.: Mitochondrial Sirtuins and Their Relationships with Metabolic Disease and Cancer. *Antioxidants & Redox Signaling*, 22, 1060-1077 (2014)  
DOI: 10.1089/ars.2014.6213
78. Monaghan, R. M., Whitmarsh, A. J.: Mitochondrial Proteins Moonlighting in the Nucleus. *Trends Biochem Sci* (2015)  
DOI: 10.1016/j.tibs.2015.10.003
79. Szczepanek, K., Lesniewsky, E. J., Larner, A. C.: Multi-Tasking: Nuclear Transcription Factors with Novel Roles in the Mitochondria. *Trends in Cell Biology*, 22, 429-437 (2012)  
DOI: 10.1016/j.tcb.2012.05.001
80. Pieczenik, S. R., Neustadt, J.: Mitochondrial dysfunction and molecular pathways of disease. *Exp Mol Pathol*, 83, 84-92 (2007)  
DOI: 10.1016/j.yexmp.2006.09.008
81. Klopstock, T., Metz, G., Yu-Wai-Man, P., Büchner, B., Gallenmüller, C., Bailie, M., Nwali, N., Griffiths, P. G., von Livonius, B., Reznicek, L., Rouleau, J., Coppard, N., Meier, T., Chinnery, P. F.: Persistence of the treatment effect of idebenone in Leber's hereditary optic neuropathy. *Brain*, 136, e230-e230 (2013)  
DOI: 10.1093/brain/awt279
82. Ahmed, N., Ronchi, D., Comi, G. P.: Genes and Pathways Involved in Adult Onset Disorders Featuring Muscle Mitochondrial DNA Instability. *International Journal of Molecular Sciences*, 16, 18054-18076 (2015)  
DOI: 10.3390/ijms160818054
83. Varga, Z. V., Ferdinandy, P., Liaudet, L., Pacher, P.: Drug-induced mitochondrial dysfunction and cardiotoxicity. *American Journal of Physiology - Heart and Circulatory Physiology*, 309, H1453-H1467 (2015)  
DOI: 10.1152/ajpheart.00554.2015
84. Ayala, A., Venero, J. L., Cano, J., Machado, A.: Mitochondrial toxins and neurodegenerative diseases. *Front Biosci*, 12, 986-1007 (2007)  
DOI: 10.2741/2119
85. Goodman, G. E., Thornquist, M. D., Balmes, J., Cullen, M. R., Meyskens, F. L., Jr., Omenn, G. S., Valanis, B., Williams, J. H., Jr.: The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. *J Natl Cancer Inst*, 96, 1743-50 (2004)  
DOI: 10.1093/jnci/djh320
86. Williams, K. J., Fisher, E. A.: Oxidation, lipoproteins, and atherosclerosis: which is wrong, the antioxidants or the theory? *Curr Opin Clin Nutr Metab Care*, 8, 139-46 (2005)  
DOI: 10.1097/00075197-200503000-00006
87. Varga, Z. V., Ferdinandy, P., Liaudet, L., Pacher, P.: Drug-induced mitochondrial dysfunction and cardiotoxicity. *Am J Physiol Heart Circ Physiol*, 309, H1453-67 (2015)  
DOI: 10.1152/ajpheart.00554.2015
88. Mikhed, Y., Daiber, A., Steven, S.: Mitochondrial Oxidative Stress, Mitochondrial DNA Damage and Their Role in Age-Related Vascular Dysfunction. *International Journal of Molecular Sciences*, 16, 15918-15953 (2015)  
DOI: 10.3390/ijms160715918
89. Au, H. C., Scheffler, I. E.: A respiration-deficient Chinese hamster cell line with a defect in mitochondrial protein synthesis: rapid turnover of some mitochondrial transcripts. *Somat Cell Mol Genet*, 23, 27-35 (1997)  
DOI: 10.1007/BF02679953

90. Elliott, H. R., Samuels, D. C., Eden, J. A., Relton, C. L., Chinnery, P. F.: Pathogenic mitochondrial DNA mutations are common in the general population. *Am J Hum Genet*, 83, 254-60 (2008)  
DOI: 10.1016/j.ajhg.2008.07.004
91. Richter, C., Park, J. W., Ames, B. N.: Normal oxidative damage to mitochondrial and nuclear DNA is extensive. *Proceedings of the National Academy of Sciences*, 85, 6465-6467 (1988)  
DOI: 10.1073/pnas.85.17.6465
92. Muftuoglu, M., Mori, M. P., Souza-Pinto, N. C. d.: Formation and repair of oxidative damage in the mitochondrial DNA. *Mitochondrion*, 17, 164-181 (2014)  
DOI: 10.1016/j.mito.2014.03.007
93. Brown, T. A., Tkachuk, A. N., Shtengel, G., Kopek, B. G., Bogenhagen, D. F., Hess, H. F., Clayton, D. A.: Superresolution Fluorescence Imaging of Mitochondrial Nucleoids Reveals Their Spatial Range, Limits, and Membrane Interaction. *Molecular and Cellular Biology*, 31, 4994-5010 (2011)  
DOI: 10.1128/MCB.05694-11
94. Kukat, C., Larsson, N.-G.: mtDNA makes a U-turn for the mitochondrial nucleoid. *Trends in Cell Biology*, 23, 457-463 (2013)  
DOI: 10.1016/j.tcb.2013.04.009
95. Szczepanowska, K., Trifunovic, A.: Different faces of mitochondrial DNA mutators. *Biochim Biophys Acta*, 1847, 1362-72 (2015)  
DOI: 10.1016/j.bbabi.2015.05.016
96. Stuart, J. A., Bourque, B. M., de Souza-Pinto, N. C., Bohr, V. A.: No evidence of mitochondrial respiratory dysfunction in OGG1-null mice deficient in removal of 8-oxodeoxyguanine from mitochondrial DNA. *Free Radical Biology and Medicine*, 38, 737-745 (2005)  
DOI: 10.1016/j.freeradbiomed.2004.12.003
97. Zheng, W., Khrapko, K., Coller, H. A., Thilly, W. G., Copeland, W. C.: Origins of human mitochondrial point mutations as DNA polymerase  $\gamma$ -mediated errors. *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*, 599, 11-20 (2006)  
DOI: 10.1016/j.mrfmmm.2005.12.012
98. De Bont, R., van Larebeke, N.: Endogenous DNA damage in humans: a review of quantitative data. *Mutagenesis*, 19, 169-85 (2004)  
DOI: 10.1093/mutage/geh025
99. de Mendoza, C., Sanchez-Conde, M., Ribera, E., Domingo, P., Soriano, V.: Could mitochondrial DNA quantitation be a surrogate marker for drug mitochondrial toxicity? *AIDS Rev*, 6, 169-80 (2004)
100. Pang, C. Y., Ma, Y. S., Wei, Y. U.: MtDNA mutations, functional decline and turnover of mitochondria in aging. *Front Biosci*, 13, 3661-75 (2008)  
DOI: 10.2741/2957
101. Prithivirajasingh, S., Story, M. D., Bergh, S. A., Geara, F. B., Kian Ang, K., Ismail, S. M., Stevens, C. W., Buchholz, T. A., Brock, W. A.: Accumulation of the common mitochondrial DNA deletion induced by ionizing radiation. *FEBS Letters*, 571, 227-232 (2004)  
DOI: 10.1016/j.febslet.2004.06.078
102. Berneburg, M., Grether-Beck, S., Kürten, V., Ruzicka, T., Briviba, K., Sies, H., Krutmann, J.: Singlet Oxygen Mediates the UVA-induced Generation of the Photoaging-associated Mitochondrial Common Deletion. *Journal of Biological Chemistry*, 274, 15345-15349 (1999)  
DOI: 10.1074/jbc.274.22.15345
103. Dumont, P., Burton, M., Chen, Q. M., Gonos, E. S., Fripiat, C., Mazarati, J.-B., Eliaers, F., Remacle, J., Toussaint, O.: Induction of replicative senescence biomarkers by sublethal oxidative stresses in normal human fibroblast. *Free Radical Biology and Medicine*, 28, 361-373 (2000)  
DOI: 10.1016/S0891-5849(99)00249-X
104. Szumiel, I.: Ionizing radiation-induced oxidative stress, epigenetic changes and genomic instability: The pivotal role of mitochondria. *International Journal of Radiation Biology*, 91, 1-12 (2015)  
DOI: 10.3109/09553002.2014.934929
105. Yang, N., Galick, H., Wallace, S. S.: Attempted base excision repair of ionizing radiation damage in human lymphoblastoid cells produces lethal and mutagenic double strand breaks. *DNA Repair*, 3, 1323-1334 (2004)  
DOI: 10.1016/j.dnarep.2004.04.014
106. Kraytsberg, Y., Kudryavtseva, E., McKee, A. C., Geula, C., Kowall, N. W., Khrapko, K.: Mitochondrial DNA deletions are abundant

- and cause functional impairment in aged human substantia nigra neurons. *Nat Genet*, 38, 518-20 (2006)  
DOI: 10.1038/ng1778
107. Kraytsberg, Y., Kudryavtseva, E., McKee, A. C., Geula, C., Kowall, N. W., Khrapko, K.: Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. *Nat Genet*, 38, 518-520 (2006)  
DOI: 10.1038/ng1778
108. Haack, T. B., Haberberger, B., Frisch, E.-M., Wieland, T., Iuso, A., Gorza, M., Strecker, V., Graf, E., Mayr, J. A., Herberg, U., Hennermann, J. B., Klopstock, T., Kuhn, K. A., Ahting, U., Sperl, W., Wilichowski, E., Hoffmann, G. F., Tesarova, M., Hansikova, H., Zeman, J., Plecko, B., Zeviani, M., Wittig, I., Strom, T. M., Schuelke, M., Freisinger, P., Meitinger, T., Prokisch, H.: Molecular diagnosis in mitochondrial complex I deficiency using exome sequencing. *Journal of Medical Genetics*, 49, 277-283 (2012)  
DOI: 10.1136/jmedgenet-2012-100846
109. Zaragoza, M. V., Brandon, M. C., Diegoli, M., Arbustini, E., Wallace, D. C.: Mitochondrial cardiomyopathies: how to identify candidate pathogenic mutations by mitochondrial DNA sequencing, MITOMASTER and phylogeny. *European Journal of Human Genetics*, 19, 200-207 (2011)  
DOI: 10.1038/ejhg.2010.169
110. Terman, A., Brunk, U. T.: Myocyte aging and mitochondrial turnover. *Exp Gerontol*, 39, 701-5 (2004)  
DOI: 10.1016/j.exger.2004.01.005
111. Gredilla, R., Bohr, V. A., Stevnsner, T.: Mitochondrial DNA repair and association with aging – An update. *Experimental Gerontology*, 45, 478-488 (2010)  
DOI: 10.1016/j.exger.2010.01.017
112. Mikhed, Y., Daiber, A., Steven, S.: Mitochondrial Oxidative Stress, Mitochondrial DNA Damage and Their Role in Age-Related Vascular Dysfunction. *Int J Mol Sci*, 16, 15918-53 (2015)  
DOI: 10.3390/ijms160715918
113. Brown, W. M., George, M., Wilson, A. C.: Rapid evolution of animal mitochondrial DNA. *Proceedings of the National Academy of Sciences*, 76, 1967-1971 (1979)  
DOI: 10.1073/pnas.76.4.1967
114. Itsara, L. S., Kennedy, S. R., Fox, E. J., Yu, S., Hewitt, J. J., Sanchez-Contreras, M., Cardozo-Pelaez, F., Pallanck, L. J.: Oxidative stress is not a major contributor to somatic mitochondrial DNA mutations. *PLoS Genet*, 10, e1003974 (2014)  
DOI: 10.1371/journal.pgen.1003974
115. Kauppila, J. H. K., Stewart, J. B.: Mitochondrial DNA: Radically free of free-radical driven mutations. *Biochimica et Biophysica Acta (BBA) - Bioenergetics*, 1847, 1354-1361 (2015)  
DOI: 10.1016/j.bbabi.2015.06.001
116. Weber, K., Wilson, J. N., Taylor, L., Brierley, E., Johnson, M. A., Turnbull, D. M., Bindoff, L. A.: A new mtDNA mutation showing accumulation with time and restriction to skeletal muscle. *Am J Hum Genet*, 60, 373-80 (1997)
117. Chaudhary, K. R., El-Sikhry, H., Seubert, J. M.: Mitochondria and the aging heart. *Journal of Geriatric Cardiology : JGC*, 8, 159-167 (2011)  
DOI: 10.3724/SP.J.1263.2011.00159
118. Pikó, L., Hougham, A. J., Bulpitt, K. J.: Studies of sequence heterogeneity of mitochondrial DNA from rat and mouse tissues: Evidence for an increased frequency of deletions/additions with aging. *Mechanisms of Ageing and Development*, 43, 279-293 (1988)  
DOI: 10.1016/0047-6374(88)90037-1
119. Stewart, J. B., Larsson, N.-G.: Keeping mtDNA in Shape between Generations. *PLoS Genetics*, 10, e1004670 (2014)  
DOI: 10.1371/journal.pgen.1004670
120. Golob, M. J., Tian, L., Wang, Z., Zimmerman, T. A., Caneba, C. A., Hacker, T. A., Song, G., Chesler, N. C.: Mitochondria DNA mutations cause sex-dependent development of hypertension and alterations in cardiovascular function. *Journal of Biomechanics*, 48, 405-412 (2015)  
DOI: 10.1016/j.jbiomech.2014.12.044
121. Farrar, G. J., Chadderton, N., Kenna, P. F., Millington-Ward, S.: Mitochondrial disorders: aetiologies, models systems, and candidate therapies. *Trends in Genetics*, 29, 488-497 (2013)  
DOI: 10.1016/j.tig.2013.05.005
122. DiMauro, S.: Mitochondrial myopathies. *Curr Opin Rheumatol*, 18, 636-41 (2006)  
DOI: 10.1097/01.bor.0000245729.17759.f2



123. Yarham, J. W., Elson, J. L., Blakely, E. L., McFarland, R., Taylor, R. W.: Mitochondrial tRNA mutations and disease. *Wiley Interdisciplinary Reviews - RNA*, 1, 304-324 (2010)  
DOI: 10.1002/wrna.27
124. Sasarman, F., Antonicka, H., Shoubbridge, E. A.: The A3243G tRNA<sup>Leu</sup>(UUR) MELAS mutation causes amino acid misincorporation and a combined respiratory chain assembly defect partially suppressed by overexpression of EFTu and EFG2. *Human Molecular Genetics*, 17, 3697-3707 (2008)  
DOI: 10.1093/hmg/ddn265
125. Linton, P. J., Gurney, M., Sengstock, D., Mentzer, R. M., Jr., Gottlieb, R. A.: This old heart: Cardiac aging and autophagy. *J Mol Cell Cardiol*, 83, 44-54 (2015)  
DOI: 10.1016/j.yjmcc.2014.12.017
126. Ahuja, P., Wanagat, J., Wang, Z., Wang, Y., Liem, D. A., Ping, P., Antoshechkin, I. A., Margulies, K. B., MacLellan, W. R.: Divergent Mitochondrial Biogenesis Responses in Human Cardiomyopathy. *Circulation*, 127, 1957-1967 (2013)  
DOI: 10.1161/CIRCULATIONAHA.112.001219
127. Meyers, D. E., Basha, H. I., Koenig, M. K.: Mitochondrial Cardiomyopathy: Pathophysiology, Diagnosis, and Management. *Texas Heart Institute Journal*, 40, 385-394 (2013)
128. Mancuso, C., Scapagini, G., Curro, D., Giuffrida Stella, A. M., De Marco, C., Butterfield, D. A., Calabrese, V.: Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. *Front Biosci*, 12, 1107-23 (2007)  
DOI: 10.2741/2130
129. Finsterer, J., Harbo, H. F., Baets, J., Van Broeckhoven, C., Di Donato, S., Fontaine, B., De Jonghe, P., Lossos, A., Lynch, T., Mariotti, C., Schols, L., Spinazzola, A., Szolnoki, Z., Tabrizi, S. J., Tallaksen, C. M., Zeviani, M., Burgunder, J. M., Gasser, T.: EFNS guidelines on the molecular diagnosis of mitochondrial disorders. *Eur J Neurol*, 16, 1255-64 (2009)  
DOI: 10.1111/j.1468-1331.2009.02811.x
130. Russell, O., Turnbull, D.: Mitochondrial DNA disease—molecular insights and potential routes to a cure. *Experimental Cell Research*, 325, 38-43 (2014)  
DOI: 10.1016/j.yexcr.2014.03.012
131. Skrzynia, C., Berg, J. S., Willis, M. S., Jensen, B. C.: Genetics and heart failure: a concise guide for the clinician. *Curr Cardiol Rev*, 11, 10-7 (2015)  
DOI: 10.2174/1573403X09666131117170446
132. Scarpulla, R. C., Vega, R. B., Kelly, D. P.: Transcriptional integration of mitochondrial biogenesis. *Trends in endocrinology and metabolism: TEM*, 23, 459-466 (2012)  
DOI: 10.1016/j.tem.2012.06.006
133. Scarpelli, M., Todeschini, A., Rinaldi, F., Rota, S., Padovani, A., Filosto, M.: Strategies for treating mitochondrial disorders: an update. *Mol Genet Metab*, 113, 253-60 (2014)  
DOI: 10.1016/j.ymgme.2014.09.013
134. Whitaker, R. M., Corum, D., Beeson, C. C., Schnellmann, R. G.: Mitochondrial Biogenesis as a Pharmacological Target: A New Approach to Acute and Chronic Diseases. *Annual Review of Pharmacology and Toxicology*, 56, null (2016)
135. Lee, S. R., Kim, H. K., Song, I. S., Youm, J., Dizon, L. A., Jeong, S. H., Ko, T. H., Hye-Jin, H., Ko, K. S., Rhee, B. D., Kim, N., Han, J.: Glucocorticoids and their receptors: Insights into specific roles in mitochondria. *Prog Biophys Mol Biol*, 112, 44-54 (2013)  
DOI: 10.1016/j.pbiomolbio.2013.04.001
136. Seo, D. Y., Lee, S. R., Kim, N., Ko, K. S., Rhee, B. D., Han, J.: Humanized animal exercise model for clinical implication. *Pflugers Arch*, 466, 1673-87 (2014)  
DOI: 10.1007/s00424-014-1496-0
137. Taivassalo, T., Gardner, J. L., Taylor, R. W., Schaefer, A. M., Newman, J., Barron, M. J., Haller, R. G., Turnbull, D. M.: Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. *Brain*, 129, 3391-401 (2006)  
DOI: 10.1093/brain/awl282
138. De Stefano, N., Matthews, P. M., Ford, B., Genge, A., Karpati, G., Arnold, D. L.: Short term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. *Neurology*, 45, 1193-1198 (1995)  
DOI: 10.1212/WNL.45.6.1193

139. Handel, E. M., Cathomen, T.: Zinc-finger nuclease based genome surgery: it's all about specificity. *Curr Gene Ther*, 11, 28-37 (2011)  
DOI: 10.2174/156652311794520120
140. Moraes, C. T.: A magic bullet to specifically eliminate mutated mitochondrial genomes from patients' cells. *EMBO Mol Med*, 6, 434-5 (2014)  
DOI: 10.1002/emmm.201303769
141. Gammage, P., Van Haute, L., Minczuk, M.: Engineered mtZFNs for Manipulation of Human Mitochondrial DNA Heteroplasmy. In: *Mitochondrial DNA*. Ed McKenzie, M. Springer New York, (2016)  
DOI: 10.1007/978-1-4939-3040-1\_11
142. Lam, B. L., Feuer, W. J., Schiffman, J. C., Porciatti, V., Vandenbroucke, R., Rosa, P. R., Gregori, G., Guy, J.: Trial End Points and Natural History in Patients With G11778A Leber Hereditary Optic Neuropathy: Preparation for Gene Therapy Clinical Trial. *JAMA ophthalmology*, 132, 428-436 (2014)  
DOI: 10.1001/jamaophthalmol.2013.7971
143. Dovydenko, I., Tarassov, I., Venyaminova, A., Entelis, N.: Method of carrier-free delivery of therapeutic RNA importable into human mitochondria: Lipophilic conjugates with cleavable bonds. *Biomaterials*, 76, 408-417 (2016)  
DOI: 10.1016/j.biomaterials.2015.10.075
144. Cannon, M. V., Irwin, M. H., Pinkert, C. A.: Mitochondrially-Imported RNA in Drug Discovery. *Drug Development Research*, 76, 61-71 (2015)  
DOI: 10.1002/ddr.21241
145. Smith, R. A., Hartley, R. C., Murphy, M. P.: Mitochondria-targeted small molecule therapeutics and probes. *Antioxid Redox Signal*, 15, 3021-38 (2011)  
DOI: 10.1089/ars.2011.3969

**Key Words:** Cardiac Manifestations, Mitochondria, Mutation, Maintenance, Mitochondrial DNA, Review

**Send correspondence to:** Jin Han, Department of Physiology, College of Medicine, Cardiovascular and Metabolic Disease Center, Inje University, Busan, Republic of Korea, Tel: 82-51-890-6727, Fax: 82-51-891-8748, E-mail: Jin Han phyhanj@inje.ac.kr